[1] YANG L, LIU S, LIU J, et al.COVID-19: immunopathogenesis and immunotherapeutics[J]. Signal Transduction and Targeted Therapy, 2020, 5(1): 1-8. [2] WANG Q, YANG L, JIN H, et al.Vaccination against COVID-19: A systematic review and Meta-analysis of acceptability and its predictors[J]. Preventive Medicine, 2021, 150: 1-9. [3] SHIMABUKURO TT, NGUYEN M, MARTIN D, et al.Safety monitoring in the vaccine adverse event reporting system (VAERS)[J]. Vaccine, 2015, 33(36): 4398-4405. [4] OLIVER SE, GARGANO JW, MARIN M, et al.The advisory committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine-United States, December 2020[J]. Morbidity and Mortality Weekly Report, 2020, 69(50): 1922-1924. [5] OLIVER SE, GARGANO JW, MARIN M, et al.The advisory committee on immunization practices' interim recommendation for use of Moderna COVID-19 vaccine-United States, December 2020[J]. Morbidity and Mortality Weekly Report, 2021, 69(5152): 1653-1656. [6] OLIVER SE, GARGANO JW, MARIN M, et al.The advisory committee on immunization practices' interim recommendation for use of Janssen COVID-19 vaccine-United States, February 2021[J]. Morbidity and Mortality Weekly Report, 2021, 70(9): 329-332. [7] HE Y, SARNTIVIJAI S, LIN Y, et al.OAE: The ontology of adverse events[J]. Journal of Biomedical Semantics, 2014, 5(1): 1-13. [8] Centers for Disease Control and Prevention. COVID data tracker[DB/OL]. (2023-03-15) [2022-06-30]. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5. [9] TWENTYMAN E, WALLACE M, ROPER LE, et al.Interim recommendation of the advisory committee on immunization practices for use of the novavax COVID-19 vaccine in persons aged ≥18 years-United States, July 2022[J]. Morb Mortal Wkly Rep, 2022, 71(31): 988-992. [10] XIE J, ZHAO L, ZHO S, et al.Statistical and ontological analysis of adverse events associated with monovalent and combination vaccines against hepatitis A and B diseases[J]. Scientific Reports, 2016, 6(1): 1-16. [11] XIE J, HE Y.Ontology-based vaccine adverse event representation and analysis[J]. Healthcare and Big Data Management, 2017, 1028: 89-103. [12] VARRICCHIO F, ISKANDER J, DESTEFANI F, et al.Understanding vaccine safety information from the vaccine adverse event reporting system[J]. The Pediatric Infectious Disease Journal, 2004, 23(4): 287-294. [13] SARNTIVIJAI S, XIANG Z, SHEDDEN KA, et al.Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines[J]. PloS One, 2012, 7(11): 1-19. [14] EVANS SJW, WALLER PC, DAVIS S.Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]. Pharmacoepidemiology and Drug Safety, 2001, 10(6): 483-486. [15] JIA Y, ZHU C, DU J, et al.Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA[J]. Peer J, 2019, 7: 1-17. [16] XIE J, CODD C, MO K, et al.Differential adverse event profiles associated with BCG as a preventive tuberculosis vaccine or therapeutic bladder cancer vaccine identified by comparative ontology-based VAERS and literature meta-analysis[J]. PloS One, 2016, 11(10): 1-20. [17] XIANG Z, COURTOT M, BRINKMAN RR, et al.OntoFox: web-based support for ontology reuse[J]. BMC Research Notes, 2010, 3(1): 1-12. [18] SIVAKUMARR, ARIVOL PV.Ontology visualization PROTÉGÉ tools-a review[J]. International Journal of Advanced Information Technology, 2011, 1(4): 1-11. [19] KLEIN NP, LEWIS N, GODDARD K, et al.Surveillance for adverse events after COVID-19 mRNA vaccination[J]. Journal of the American Medical Association, 2021, 326(14): 1390-1399. [20] SINGH A, KHILLAN R, MISHRA Y, et al.The safety profile of COVID-19 vaccinations in the United States[J]. American Journal of Infection Control, 2022, 50(1): 15-19. [21] FOLTRAN D, DELMAS C, FLUMIAN C, et al.Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines[J]. Eur Heart J Qual Care Clin Outcomes, 2022, 8(2): 99-103. [22] AYE YN, MAI AS, ZHANG A, et al.Acute myocardial infarction and myocarditis following COVID-19 vaccination[J]. QJM: An International Journal of Medicine, 2021, 116(4): 279-283. [23] CIABATTINI A, NARDINI C, SANTORO F, et al.Vaccination in the elderly: the challenge of immune changes with aging[J]. Semin Immunol, 2018, 40(3): 83-94. [24] ANDERSON EJ, ROUPHAEL NG, WIDGE AT, et al.Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults[J]. New England Journal of Medicine, 2020, 383(25): 2427-2438. [25] GUO L, SHI Z, ZHANG Y, et al.Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis[J]. Diabetes Research and Clinical Practice, 2020, 166: 1-7. [26] WIBAWA T.COVID-19 vaccine research and development: ethical issues[J]. Trop Med Int Health, 2021, 26(1): 14-19. |